Ovarian cancer biomarker performance in prostate, lung, colorectal, and ovarian cancer screening trial specimens. - Wikidata - wikimedia - TriplyDB

Ovarian cancer biomarker performance in prostate, lung, colorectal, and ovarian cancer screening trial specimens.

Ovarian cancer biomarker performance in prostate, lung, colorectal, and ovarian cancer screening trial specimens.

http://www.wikidata.org/entity/Q34895083

about

Why Your New Cancer Biomarker May Never Work: Recurrent Patterns and Remarkable Diversity in Biomarker Failures In 2014, can we do better than CA125 in the early detection of ovarian cancer?The emerging role of HE4 in the evaluation of epithelial ovarian and endometrial carcinomas Ovarian cancer screening--current status, future directions Protein kinase A activity and anchoring are required for ovarian cancer cell migration and invasion Evaluation of DNA from the Papanicolaou test to detect ovarian and endometrial cancers Comprehensive serum profiling for the discovery of epithelial ovarian cancer biomarkers Safety and Outcome Measures of First-in-Human Intraperitoneal α Radioimmunotherapy With 212Pb-TCMC-Trastuzumab.Immunosignature system for diagnosis of cancer.HIF-1α binding to AEG-1 promoter induced upregulated AEG-1 expression associated with metastasis in ovarian cancer.MUC16 (CA125): tumor biomarker to cancer therapy, a work in progress Proteomic biomarkers in combination with CA 125 for detection of epithelial ovarian cancer using prediagnostic serum samples from the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial.Control values of ovarian cancer tumor markers and standardisation of a protocol for sampling peritoneal fluid and performing washing during laparoscopy.The failure of protein cancer biomarkers to reach the clinic: why, and what can be done to address the problem?The glycolyzer: automated glycan annotation software for high performance mass spectrometry and its application to ovarian cancer glycan biomarker discovery.Cancer-associated autoantibodies to MUC1 and MUC4--a blinded case–control study of colorectal cancer in UK collaborative trial of ovarian cancer screening.Protein biomarkers of ovarian cancer: the forest and the trees A framework for evaluating biomarkers for early detection: validation of biomarker panels for ovarian cancer.Laboratory detective work identifies a mishandling problem in sample aliquoting Challenges related to developing serum-based biomarkers for early ovarian cancer detection.Application of proteomics to cancer early detection Autoantibody signature for the serologic detection of ovarian cancer Building multi-marker algorithms for disease prediction-the role of correlations among markers.Aberrant glycosylation associated with enzymes as cancer biomarkers.Validation of LRG1 as a potential biomarker for detection of epithelial ovarian cancer by a blinded study Kaempferol inhibits VEGF expression and in vitro angiogenesis through a novel ERK-NFκB-cMyc-p21 pathway Discovery of serum biomarkers of ovarian cancer using complementary proteomic profiling strategies.Potential role of HE4 in multimodal screening for epithelial ovarian cancer Decreased levels of serum glutathione peroxidase 3 are associated with papillary serous ovarian cancer and disease progression.Proteomic analyses of human plasma: Venus versus Mars.Serum human epididymis protein 4 and risk for ovarian malignancy algorithm as new diagnostic and prognostic tools for epithelial ovarian cancer management Risk Algorithm Using Serial Biomarker Measurements Doubles the Number of Screen-Detected Cancers Compared With a Single-Threshold Rule in the United Kingdom Collaborative Trial of Ovarian Cancer Screening.A xenograft mouse model coupled with in-depth plasma proteome analysis facilitates identification of novel serum biomarkers for human ovarian cancer Designing early detection programs for ovarian cancer.Systemic Metabolomic Changes in Blood Samples of Lung Cancer Patients Identified by Gas Chromatography Time-of-Flight Mass Spectrometry Evaluation of ovarian cancer remission markers HE4, MMP7 and Mesothelin by comparison to the established marker CA125 Optimizing molecular-targeted therapies in ovarian cancer: the renewed surge of interest in ovarian cancer biomarkers and cell signaling pathways.Evaluating Serum Markers for Hormone Receptor-Negative Breast Cancer.Multianalyte assay systems in the differential diagnosis of ovarian cancer.Upregulation of spondin-2 predicts poor survival of colorectal carcinoma patients

P2860

Q24289009-B2E020EB-F1C5-43E0-BDCF-E24ED5564549 Q26825152-9B045CAA-0BCB-414B-8EC6-759DBF37B875 Q26992102-F629EBA0-9DAB-4183-923A-05342A233220 Q27004471-90EEF3CE-D3CB-455D-9B46-7931BCB4D95E Q27315878-A2FD4414-8B58-4E99-A038-8709DE6FD029 Q28282973-F8D16A99-0204-46B4-A808-DD593467FAB3 Q28741004-79C411FE-D921-4E37-B675-6844C75908F1 Q30490448-F0BDCC1B-B415-498D-BAC3-9E1095592CB6 Q30585860-2EC2196B-02AC-4E40-BEC3-A9F2D69199F1 Q33679589-87B6C9BF-DD0C-4EE1-98FE-3B5F18ABB29E Q33713506-62DCBBC4-6D51-4BBF-B4A5-733A57AA1157 Q33946840-9AFB571C-E94C-4728-9C13-0E46A58DFB30 Q34204891-22976C2C-E945-422D-B162-708F7EFA73FF Q34372843-5D60EAE2-90E3-422D-9A9B-F9A9F1E933B6 Q34383959-367918BE-F81A-428C-BB8F-FE0085B83D66 Q34522222-6DA17195-8C4B-4834-BC02-6212FBC9ED26 Q34634143-F1933A64-004B-4EA0-9225-32514F72ECDC Q34672941-62152054-D63C-447C-85C0-05658671ABA4 Q34768348-E5E82A4B-4AE0-48FA-A64C-E49CDA8D1F2B Q34796143-BCFB047C-98F8-424B-AC0D-234593C175DF Q35053031-6319B465-8CD0-4DDE-9EF5-4C57BFFBEAA6 Q35100846-921AE62D-5266-4658-9CA6-1FCEC07984B7 Q35203327-8DC28656-BAA9-4734-BC2B-CA165BB333DC Q35206309-656E3552-2D8F-4D16-A230-6104FD9DA983 Q35208879-BA6CB210-00B4-4361-997D-BAB951E0B79F Q35210298-A0DC1F46-8BA1-4B1C-8A38-7BCED1A151D4 Q35309119-0A7ADEF5-9770-4BA3-8903-4B7E74B65BF2 Q35499974-FC3DE2FD-A311-4AA3-A2FF-EDBCA2DFBE62 Q35541079-96B2EAC7-E09E-4A26-AEFE-FE307ABC814F Q35605878-A2F75F7A-69EC-4E12-B54A-6BB6B944D41B Q35612779-BA44F040-E457-4635-9D20-B9BBD84A6B61 Q35721991-B2D3FF1F-3026-4D8A-A95C-96320209106F Q35736782-545DB2CD-480B-4A43-9D31-FEACA9BD0981 Q35760155-AE121FC0-0B57-40D9-9E2A-DAD85BC2E423 Q35829888-F5FED90F-F408-4443-BBEE-8A12AEFD0CD4 Q35830931-2BEBEC87-96E5-4455-8510-E03111378BED Q35837949-7E1CA1EC-13AD-48E4-B1F9-54DF90D1566D Q35840714-31C2FDBF-DA2A-4512-B5C3-62CE1FA0E887 Q35854476-7DB516EB-1959-4A13-8BC6-68CE1B3A1461 Q36020932-E0317DF3-F591-46B5-AC69-0E39296A8C92

P2860

Ovarian cancer biomarker performance in prostate, lung, colorectal, and ovarian cancer screening trial specimens.

http://www.wikidata.org/entity/Q34895083

description

2011 nî lūn-bûn

@nan

2011 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի մարտին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Ovarian cancer biomarker perfo ...... cer screening trial specimens.

@ast

Ovarian cancer biomarker perfo ...... cer screening trial specimens.

@en

Ovarian cancer biomarker perfo ...... cer screening trial specimens.

@nl

type

label

Ovarian cancer biomarker perfo ...... cer screening trial specimens.

@ast

Ovarian cancer biomarker perfo ...... cer screening trial specimens.

@en

Ovarian cancer biomarker perfo ...... cer screening trial specimens.

@nl

prefLabel

Ovarian cancer biomarker perfo ...... cer screening trial specimens.

@ast

Ovarian cancer biomarker perfo ...... cer screening trial specimens.

@en

Ovarian cancer biomarker perfo ...... cer screening trial specimens.

@nl

P1433

Q34895083-E1B80DE2-1E64-43EE-B3B4-8D49B19A06FE

P1476

Q34895083-3AE5B9F2-3EC8-43EC-B23F-5F32061D6EEB

P2093

Q34895083-024246AC-9EFE-4FAD-9F92-D2EEE3F54C79

Q34895083-1F87D37F-BCD6-4CC4-BED6-1AEBD080FA41

Q34895083-298F017C-AD51-497B-B893-6C4F3758815F

Q34895083-2A0CD78D-66B0-45F7-86B4-90054032956E

Q34895083-5013CC23-A66C-4405-BC4F-EA15A431ABAD

Q34895083-50B26A07-24F5-45E3-AD5F-5AE6AC44809D

Q34895083-58E8B812-993B-4296-961C-32196CE7B06E

Q34895083-75B4D741-7FF5-49ED-B665-858C07F1377D

Q34895083-8BEEF600-F206-4AF2-8EA1-73FEAA075633

Q34895083-B2513CC5-C9C2-4729-B373-1145CBCDD05B

P2860

Q34895083-0FE7D538-2512-478A-B99A-D8B6A0945019

Q34895083-1E1D13A2-AB89-4DBF-B52F-54420141F559

Q34895083-2B48737D-2611-4D0B-8249-590C4E33EFBC

Q34895083-36195C7A-66DC-43F2-85AC-43F9EB1C656C

Q34895083-3F0B2EBD-96CA-402B-B7CB-9E7049A62E2F

Q34895083-43A29FA0-A8E1-4012-80C8-3F0865DC36AC

Q34895083-5D670CF5-50B4-4163-AFCC-1E226F2789BB

Q34895083-7002169F-3753-40D6-8532-62787851CD57

Q34895083-72CF331C-B1A4-460A-9EA9-D389A2712908

Q34895083-732068A9-53CC-4592-9471-C53EEBF1D90C

P304

Q34895083-76A254FF-7317-48CD-AC02-7EEEAD69AF6A

P31

Q34895083-1B6BAF53-E19A-49EB-A98B-789E1403DF48

P356

Q34895083-A95093F1-8D38-493A-B0AB-150CC4577A58

P433

Q34895083-7DCAD648-0622-438E-887B-BF1B7C770CC5

P478

Q34895083-D5276E4F-2BE4-4475-9A35-00CEC5885120

P50

Q34895083-96D23426-75CC-4437-A032-C22F0A5B1691

Q34895083-F7BDD28F-CCEC-4644-8222-8884635CBB76

Q34895083-FE4FBF11-EDEC-4D1A-B871-4B69787787A9

P577

Q34895083-16ED1930-5265-4E9A-A921-03A0111B94E6

P5875

Q34895083-252B1EAA-4DFB-4553-9F0F-623CD54E9E93

P698

Q34895083-297B717A-6664-4668-97B6-84B37F9AAD8E

P921

Q34895083-6F031917-506F-48B2-958B-46124E243A73

Q34895083-7F28D3B8-8245-4D06-805E-C5FF4448E994

P932

Q34895083-B5F5F1DC-7682-47DD-AB5B-7040379D3486

P356

1940-6207.CAPR-10-0195

P1433

Cancer Prevention Research

P1476

Ovarian cancer biomarker perfo ...... cer screening trial specimens.

@en

P2093

Andrew K Godwin

http://www.w3.org/2001/XMLSchema#string

Anna E Lokshin

http://www.w3.org/2001/XMLSchema#string

Christine D Berg

http://www.w3.org/2001/XMLSchema#string

Christos Patriotis

http://www.w3.org/2001/XMLSchema#string

Claire S Zhu

http://www.w3.org/2001/XMLSchema#string

Daniel W Cramer

http://www.w3.org/2001/XMLSchema#string

David C Ward

http://www.w3.org/2001/XMLSchema#string

Gil Mor

http://www.w3.org/2001/XMLSchema#string

Karen H Lu

http://www.w3.org/2001/XMLSchema#string

Mark D Thornquist

http://www.w3.org/2001/XMLSchema#string

P2860

Results from four rounds of ovarian cancer screening in a randomized trial

Design and evolution of the data management systems in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial.

Use of proteomic patterns in serum to identify ovarian cancer.

A recipe for proteomics diagnostic test development: the OVA1 test, from biomarker discovery to FDA clearance.

Assessing lead time of selected ovarian cancer biomarkers: a nested case-control study

Serum protein markers for early detection of ovarian cancer

Coordination and management of a large multicenter screening trial: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial.

Death review process in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial.

Phases of biomarker development for early detection of cancer.

A framework for evaluating biomarkers for early detection: validation of biomarker panels for ovarian cancer.

P304

365-374

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1940-6207.CAPR-10-0195

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

4

http://www.w3.org/2001/XMLSchema#string

P50

Patricia Hartge

Eleftherios P. Diamandis

P577

2011-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

50270765

http://www.w3.org/2001/XMLSchema#string

P698

21372036

http://www.w3.org/2001/XMLSchema#string

P921

P932

3085251

http://www.w3.org/2001/XMLSchema#string